Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cel-Sci Corporation Common Stock (NY: CVM )

0.4310 +0.0161 (+3.88%)
Official Closing Price Updated: 8:00 PM EST, Jan 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 Next >
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Hits Intraday Highs as Treasury Yields Retreat
The Dow Jones Industrial Average is 216 points lower at midday, erasing this morning's marginal gains amid growing pressures on energy and transportation stocks. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
44 Stocks Moving In Monday's Mid-Day Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy. Marin Software... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
CEL-SCI's Immunotherapy Achieves Survival Benefit Of 14% Exceeding Pre-Defined 10% In Head & Cancer Patients
CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell... 
Via Benzinga
CEL-SCI’s Multikine® Immunotherapy Produces Significant 14.1% 5-Year Survival Benefit (62.7% Vs 48.6%) in the Group Receiving Surgery Plus Radiotherapy in a Landmark Head and Neck Cancer Phase 3 Study
From CEL-SCI Corporation
Via Business Wire
24 Stocks Moving in Monday's Pre-Market Session
Gainers Intellia Therapeutics, Inc. (NASDAQ: NTLA) rose 28.9% to $114.49 in pre-market trading. Intellia Therapeutics and Regeneron Pharmaceuticals disclosed positive interim... 
Via Benzinga
CEL-SCI Corporation Invites Participants to Pre-Submit Questions for Annual Shareholder Meeting
From CEL-SCI Corporation
Via Business Wire
Cel-Sci Stock Shows Market Leadership With Jump To 81 RS Rating
Cel-Sci sees its Relative Strength Rating hit the 80-plus level. 
Via Investor's Business Daily
CEL-SCI Announces the Closing of $31.7 Million Bought Deal Offering
From CEL-SCI Corporation
Via Business Wire
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares surged 388.2% to close at $10.79 on Wednesday in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID... 
Via Benzinga
CEL-SCI Stock Drops After Raising $37.1M Via Secondary Equity Offering
CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at... 
Via Benzinga
48 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) shares jumped 371% to $10.41 in reaction to Zacks Article 'AEMD: First Ever In Vivo Removal Of COVID Virus From Bloodstream Of An... 
Via Benzinga
CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million
From CEL-SCI Corporation
Via Business Wire
CEL-SCI Announces Bought Deal Offering
From CEL-SCI Corporation
Via Business Wire
Can You Count on This Popular Reddit Cancer-Treatment Stock?
Big news is coming for CEL-SCI, and we don't know which way the stock will move. 
Via The Motley Fool
Cel-Sci Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Cel-Sci stock saw an improvement to its Relative Strength Rating on Thursday, rising from 79 to 87, making the stock a potential watchlist candidate. 
Via Investor's Business Daily
CEL-SCI Corporation Reports Second Quarter Fiscal 2021 Financial Results
From CEL-SCI Corporation
Via Business Wire
58 Biggest Movers From Yesterday
Gainers Peabody Energy Corporation (NYSE: BTU) shares gained 32.3% to settle at $8.60 on Monday. Nuvve Holding Corp. (NASDAQ: NVVE) shares jumped 30.9% to close at $10.80 on... 
Via Benzinga
Struggling Big Tech Puts More Pressure on Markets
The Dow Jones Industrial Average is off 163 points midday as Big Tech's march lower resumes, pouring cold water on the broader market. 
Via Talk Markets
Topics Stocks
Exposures US Equities
40 Stocks Moving In Monday's Mid-Day Session
Gainers Nuvve Holding Corp. (NASDAQ: NVVE) shares surged 22.2% to $10.08 after the company announced an agreement with Evolve Transition Infrastructure and Stonepeak to purse a $... 
Via Benzinga
Biotech Cel-Sci Stock Joins Rank Of Stocks With RS Ratings Over 90
Cel-Sci shows rising price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
44 Biggest Movers From Yesterday
Gainers KnowBe4, Inc. (NASDAQ: KNBE) shares jumped 50.9% to close at $24.14 on Thursday after the company priced its IPO at $16 per share. Neuropace, Inc. (NASDAQ: NPCE) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
30 Stocks Moving In Thursday's Mid-Day Session
Gainers Teradata Corporation (NYSE: TDC) shares jumped 28.6% to $51.29 after the company raised its Q1 earnings guidance. SeaChange International, Inc. (NYSE: SEAC) gained 19.6... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.